公开(公告)号：US09610354B2

公开(公告)日：2017-04-04

申请号：US14112317

申请日：2012-04-16

Applicant: Takashi Okada ,  Shin'ichi Takeda ,  Hiromi Kinoh

Inventor： Takashi Okada ,  Shin'ichi Takeda ,  Hiromi Kinoh

IPC: A61K47/42 ,  A61K9/14 ,  A61K9/51 ,  A61K31/7088 ,  A61K31/713 ,  A61K47/26

CPC classification number: A61K9/5184 ,  A61K9/14 ,  A61K31/7088 ,  A61K31/713 ,  A61K47/26 ,  A61K47/42 ,  A61K48/0008 ,  A61K48/0091 ,  C12N5/00 ,  C12N7/00 ,  C12N15/113 ,  C12N2310/14 ,  C12N2320/32 ,  C12N2510/02 ,  C12N2710/10042 ,  C12N2750/00042 ,  C12N2750/00051 ,  C12N2750/14142

Abstract: An object of the present invention is to develop and provide a method for conveniently introducing a nucleic acid, a peptide, and/or a low-molecular-weight compound into an empty capsid with viral early infection activities kept. The present invention provides a method for producing a drug delivery particle, comprising the steps of: mixing an empty capsid or an empty particle with a drug including a nucleic acid, a peptide, and/or a low-molecular-weight compound in a solution comprising 0.1 to 20% of a surfactant; and keeping the obtained mixed solution at −5 to 50° C. to introduce the drug into the empty capsid or the empty particle.

公开(公告)号：US20140044794A1

公开(公告)日：2014-02-13

申请号：US14112317

申请日：2012-04-16

Applicant: Takashi Okada ,  Shin'ichi Takeda ,  Hiromi Kinoh

Inventor： Takashi Okada ,  Shin'ichi Takeda ,  Hiromi Kinoh

IPC: A61K47/42 ,  A61K9/14

CPC classification number: A61K9/5184 ,  A61K9/14 ,  A61K31/7088 ,  A61K31/713 ,  A61K47/26 ,  A61K47/42 ,  A61K48/0008 ,  A61K48/0091 ,  C12N5/00 ,  C12N7/00 ,  C12N15/113 ,  C12N2310/14 ,  C12N2320/32 ,  C12N2510/02 ,  C12N2710/10042 ,  C12N2750/00042 ,  C12N2750/00051 ,  C12N2750/14142

Abstract: An object of the present invention is to develop and provide a method for conveniently introducing a nucleic acid, a peptide, and/or a low-molecular-weight compound into an empty capsid with viral early infection activities kept. The present invention provides a method for producing a drug delivery particle, comprising the steps of: mixing an empty capsid or an empty particle with a drug including a nucleic acid, a peptide, and/or a low-molecular-weight compound in a solution comprising 0.1 to 20% of a surfactant; and keeping the obtained mixed solution at −5 to 50° C. to introduce the drug into the empty capsid or the empty particle.

Abstract translation: 本发明的目的是开发并提供一种便利地将核酸，肽和/或低分子量化合物引入具有保持的病毒性早期感染活性的空衣壳中的方法。 本发明提供一种制备药物递送颗粒的方法，其包括以下步骤：将空衣壳或空粒子与包含核酸，肽和/或低分子量化合物的药物在溶液中混合 包含0.1-20％的表面活性剂; 并将所得混合溶液保持在-5至50℃以将药物引入空的衣壳或空的颗粒中。

公开(公告)号：US20120329046A1

公开(公告)日：2012-12-27

申请号：US13461075

申请日：2012-05-01

Applicant: Shin'ichi Takeda ,  Akinori Nakamura ,  Masanori Kobayashi ,  Takashi Okada

Inventor： Shin'ichi Takeda ,  Akinori Nakamura ,  Masanori Kobayashi ,  Takashi Okada

IPC: G01N33/566 ,  C12Q1/68

CPC classification number: C12Q1/6883 ,  C12Q2600/136 ,  C12Q2600/158 ,  G01N33/5023 ,  G01N33/5061 ,  G01N33/6869 ,  G01N33/6872 ,  G01N2333/5412 ,  G01N2333/5421 ,  G01N2800/2878

Abstract: Novel markers associated with the development of muscular dystrophy that elucidate the mechanisms of muscular dystrophy development and provide a means for diagnosis and treatment of muscular dystrophy are presented. The expression level of one or more markers selected from the group consisting of c-Fos, EGR1, IL-6, and IL-8 in a sample obtained from the subject can be compared with a reference value to diagnose muscular dystrophy in the subject.

Abstract translation: 提出了与肌营养不良发展相关的新型标志物，其阐明肌营养不良发展的机制并提供用于诊断和治疗肌营养不良症的手段。 可以将从受试者获得的样品中选自c-Fos，EGR1，IL-6和IL-8的一种或多种标志物的表达水平与参考值进行比较，以诊断受试者的肌营养不良症。

公开(公告)号：US20110318764A1

公开(公告)日：2011-12-29

申请号：US13255120

申请日：2010-03-08

Applicant: Yoshihiro Urade ,  Kosuke Aritake ,  Toshihiko Maruyama ,  Shinya Kamauchi ,  Shin'ichi Takeda ,  Akinori Nakamura

Inventor： Yoshihiro Urade ,  Kosuke Aritake ,  Toshihiko Maruyama ,  Shinya Kamauchi ,  Shin'ichi Takeda ,  Akinori Nakamura

IPC: G01N33/53 ,  H01J49/26 ,  G01N21/64 ,  C07K16/26 ,  C12Q1/25

CPC classification number: G01N33/6893 ,  G01N30/7233 ,  G01N2030/8813 ,  G01N2800/28 ,  G01N2800/2878

Abstract: Muscle degenerative diseases can be detected in the early stage and the therapeutic efficacy of a therapeutic agent and/or a therapy method for the diseases can be determined by measuring 11,15-dioxo-9α-hydroxy-2,3,4,5-tetranorprostan-1,20-dioic acid (referred to as “Tetranor-PGDM”, hereinbelow) in a sample isolated from a subject.

Abstract translation: 可以在早期检测肌肉退行性疾病，治疗剂的治疗效果和/或治疗方法可以通过测量11,15-二氧代-9α-羟基-2,3,4,5-四氢 - 在受试者分离的样品中的四前驱体-1,20-二酸（以下称为“Tetranor-PGDM”）。

公开(公告)号：US09079934B2

公开(公告)日：2015-07-14

申请号：US13819520

申请日：2011-08-31

Applicant: Naoki Watanabe ,  Youhei Satou ,  Shin'ichi Takeda ,  Tetsuya Nagata

Inventor： Naoki Watanabe ,  Youhei Satou ,  Shin'ichi Takeda ,  Tetsuya Nagata

IPC: C07H21/02 ,  C07H21/04 ,  A61K31/70 ,  C12N15/11 ,  C12N15/113 ,  C07H21/00 ,  C12Q1/68

CPC classification number: C07H21/04 ,  C07H21/00 ,  C12N15/111 ,  C12N15/113 ,  C12N2310/11 ,  C12N2310/3145 ,  C12N2310/315 ,  C12N2310/321 ,  C12N2310/3525 ,  C12N2320/33

Abstract: The present invention provides an oligomer which efficiently enables to cause skipping of the 53rd exon in the human dystrophin gene. Also provided is a pharmaceutical composition which causes skipping of the 53rd exon in the human dystrophin gene with a high efficiency.

Abstract translation: 本发明提供了有效地使第53外显子在人肌营养不良蛋白基因中跳过的低聚物。 还提供了一种药物组合物，其以高效率使得第53外显子在人肌营养不良蛋白基因中跳过。

公开(公告)号：US08658390B2

公开(公告)日：2014-02-25

申请号：US13255120

申请日：2010-03-08

Applicant: Yoshihiro Urade ,  Kosuke Aritake ,  Toshihiko Maruyama ,  Shinya Kamauchi ,  Shin'ichi Takeda ,  Akinori Nakamura

Inventor： Yoshihiro Urade ,  Kosuke Aritake ,  Toshihiko Maruyama ,  Shinya Kamauchi ,  Shin'ichi Takeda ,  Akinori Nakamura

IPC: G01N33/53

CPC classification number: G01N33/6893 ,  G01N30/7233 ,  G01N2030/8813 ,  G01N2800/28 ,  G01N2800/2878

Abstract: Muscle degenerative diseases can be detected in the early stage and the therapeutic efficacy of a therapeutic agent and/or a therapy method for the diseases can be determined by measuring 11,15-dioxo-9α-hydroxy-2,3,4,5-tetranorprostan-1,20-dioic acid (referred to as “Tetranor-PGDM”, hereinbelow) in a sample isolated from a subject.

Abstract translation: 可以在早期检测肌肉退行性疾病，治疗剂的治疗效果和/或治疗方法可以通过测量11,15-二氧代-9α-羟基-2,3,4,5-四 在受试者分离的样品中的四前驱体-1,20-二酸（以下称为“Tetranor-PGDM”）。

公开(公告)号：US20130211062A1

公开(公告)日：2013-08-15

申请号：US13819520

申请日：2011-08-31

Applicant: Naoki Watanabe ,  Youhei Satou ,  Shin'ichi Takeda ,  Tetsuya Nagata

Inventor： Naoki Watanabe ,  Youhei Satou ,  Shin'ichi Takeda ,  Tetsuya Nagata

IPC: C07H21/04 ,  C07H21/00

CPC classification number: C07H21/04 ,  C07H21/00 ,  C12N15/111 ,  C12N15/113 ,  C12N2310/11 ,  C12N2310/3145 ,  C12N2310/315 ,  C12N2310/321 ,  C12N2310/3525 ,  C12N2320/33

Abstract: The present invention provides a pharmaceutical composition which causes skipping of the 53rd exon in the human dystrophin gene with a high efficiency.The present invention provides an oligomer which efficiently enables to cause skipping of the 53rd exon in the human dystrophin gene.